Clinical Trial Update: Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates the use of peginterferon alfa-2a to enhance anti-leukemic responses after allogeneic transplantation in acute myeloid leukemia; study pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-06